Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20100009355SELECTIVE AMPLIFICATION OF MINORITY MUTATIONS USING PRIMER BLOCKING HIGH-AFFINITY OLIGONUCLEOTIDES
US 14.01.2010
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No 12282504 Applicant Inventor Kolodney Michael S.

In certain embodiments this invention pertains to methods of detecting and/or quantifying rare mutant nucleic acids in populations of nucleic acids in which the wild-type nucleic acids are in substantially greater abundance than the rare mutants. In various embodiments the methods utilize short high affinity oligonucleotides targeted to the wild type rather than the minority or mutant sequence. Rather than directly detecting mutant DNA, these probes block detection of wild type DNA. These “blocker” probes can be used in combination with longer “detection” probes or PCR primers to amplify and/or identify the minority mutation in, e.g., clinical specimens. The combination of short high affinity blocker probes and longer, lower affinity detection probes eliminates the single base specificity/complexity tradeoff in the design of nucleic acid probes.

2.101648958Preparation method of dianhydride monomer containing chiral dianhydro-hexitol
CN 17.02.2010
Int.Class C07D 493/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
493Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No 200910092469.1 Applicant Tsinghua University Inventor Chen Zhen
The invention relates to a preparation method of dianhydride monomer containing chiral dianhydro-hexitol, belonging to the technical field of high polymer materials. The preparation method comprises the following steps: adding chiral dianhydro-hexitol into anhydrous solvent according to the mol ratio between the chiral dianhydro-hexitol and the solvent of 1: 30-40; adding acid absorbent into chiral dianhydro-hexitol solution according to the mol ratio between the chiral dianhydro-hexitol and the acid absorbent of 1: 1-1.2; adding 1,2,4-trimellitic anhydride acyl chloride into the mixture according to the mol ratio between the chiral dianhydro-hexitol and the 1,2,4-trimellitic anhydride acyl chloride of 1: 2.1-2.4, reacting under stirring at a temperature between 0 DEG C and room temperature; carrying out air pump filtration on the reactant, slowly dripping filtrate into petroleum ether, and separating white solid out. The preparation method has the advantages of low material cost, mildpreparation reaction conditions, easy control, high reaction conversion ratio and simpler purification after reaction.
3.2010017146METHOD FOR PRODUCING AZIDE SUGAR BY MICROORGANISM REACTION AND ENZYME REACTION
JP 28.01.2010
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
Appl.No 2008181469 Applicant KISHOTO SEISAN GIJUTSU KENKYUSHO:KK Inventor IKUMORI TAKESHI

PROBLEM TO BE SOLVED: To provide a bacterium that belongs to the genus Klebsiella and has ability of producing L-tagatose from galactitol.

SOLUTION: The bacterium of the genus Klebsiella has ability of using 6-azide hexitol as a raw material in which the 6-position of hexose is azidated, oxidizing the 2-position and forming 6-azide ketohexose. Moreover, the bacterium of the genus Klebsiella has ability of isomerizing 6-azide ketohexose and producing 6-azide aldohexose. The 6-azide polyol dehydrogenase is produced by the bacterium, acts on 6-azide polyol and oxidizes the 2-position to give ketose so as to form 6-azide ketohexose. The 6-azide aldose isomerase isomerizes 6-azide ketohexose to produce 6-azide aldohexose.

COPYRIGHT: (C)2010,JPO&INPIT

4.WO/2010/125004CDK INHIBITOR SALTS
WO 04.11.2010
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/EP2010/055463 Applicant NERVIANO MEDICAL SCIENCES S.R.L. Inventor ZAMPIERI, Massimo
The present invention relates to novel crystalline form(s) of water-soluble salts and of free base of a cdk inhibitor. Such crystal salts are for example fumarate, L-malate, maleate, succinate, adipate, malonate, glycolate, phosphate, mesylate, L-lactate, hydrochloride, di-hydrochloride, tri-hydrochloride. Hydrates and polymorphs of such new salt forms, a process for their preparation, their utility in therapy and to the pharmaceutical compositions containing them are also claimed and described in the present application.
5.101663025Stabilised pharmaceutical composition containing pregabaline
CN 03.03.2010
Int.Class A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
Appl.No 200880012632.2 Applicant Ratiopharm GmbH Inventor Schulze-nahrup Julia
Solid pharmaceutical composition containing: (a) pregabaline as active principle and (b) one or several pharmaceutical auxiliary agents, the composition being essentially free from saccharides and comprising no further amino acids, apart from pregabaline.
6.2010524991プレガバリンを含有する安定化された医薬組成物
JP 22.07.2010
Int.Class A61K 31/197
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
Appl.No 2010504536 Applicant ラシオファルム ゲーエムベーハー Inventor シュルツェナールプ、ジュリア

(a)活性成分としてのプレガバリン、及び(b)1種又は数種の医薬補助剤を含有する固体医薬組成物であって、糖類を本質的に含まず、プレガバリンは別として、それ以外のアミノ酸を含まない組成物。

7.200901365СТАБИЛИЗИРОВАННАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРЕГАБАЛИН
EA 30.04.2010
Int.Class A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
Appl.No 200901365 Applicant РАЦИОФАРМ ГМБХ Inventor Шульце-Наруп Юлия

Твердая фармацевтическая композиция, содержащая: (a) прегабалин в качестве действующего вещества и (b) одно или несколько фармацевтических вспомогательных веществ, при этом композиция, по существу, не содержит сахариды и не содержит дополнительные аминокислоты кроме прегабалина.

8.WO/2010/115993TRICYCLO-DNA ANTISENSE OLIGONUCLEOTIDES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE
WO 14.10.2010
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/EP2010/054735 Applicant ASSOCIATION INSTITUT DE MYOLOGIE Inventor SCHÜMPERLI, Daniel
Provided are tricyclo-DNA (tc-DNA) AON and methods employing tc-DNA AON for modifying splicing events that occur during pre-mRNA processing. Tricyclo-DNA (tc-DNA) AON are described that may be used to facilitate exon skipping or to mask intronic silencer sequences and/or terminal stem-loop sequences during pre-mRNA processing and to target RNase-mediated destruction of processed mRNA. Tc-DNA AON described herein may be used in methods for the treatment of Duchenne Muscular Dystrophy by skipping a mutated exon 23 or exon 51 within a dystrophin gene to restore functionality of a dystrophin protein; in methods for the treatment of Spinal Muscular Atrophy by masking an intronic silencing sequence and/or a terminal stem-loop sequence within an SMN2 gene to yield modified functional SMN2 protein, including an amino acid sequence encoded by exon 7, which is capable of at least partially complementing a non-functional SMNl protein; and in methods for the treatment of Steinert's Myotonic Dystrophy by targeting the destruction of a mutated DMl mRNA comprising 3 '-terminal CUG repeats.
9.2010515707Dbaitおよびその単独使用
JP 13.05.2010
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No 2009545182 Applicant サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィク Inventor デユトレックス,マリー

本発明は、哺乳動物細胞における二本鎖切断(DSB)のDNA修復に干渉する組成物および方法に関する。本発明は、DNA DSB検知、シグナル伝達および/または修復経路、特にDSB修復の非相同末端結合(NHEJ)経路に関与する酵素のホロ複合体(holocomplex)を引き寄せる、または、奪うことにより作用する二本鎖核酸分子を開示する。本発明は、死を誘発するために、有効量で腫瘍細胞の核に導入される単独の抗癌薬物としてのこれらの分子の使用を開示する。

10.20100137219Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US 03.06.2010
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No 12117872 Applicant IDEXX Laboratories, Inc. Inventor Krah, III Eugene Regis

The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.